

- **Name:** Hye Ryun KIM
 - **Current Position & Affiliation:** Yonsei Cancer Center
 - **Country:** Korea
-

• Educational Background:

1997-2001: Yonsei University College of Technology, department of biotechnology.
2001-2005: Yonsei University College of Medicine, Seoul, Republic of Korea
2007-2010: Master, Department of Medicine, Yonsei University College of Medicine
2011-2015: Doctor of Philosophy, Department of Medicine, Graduate School of Yonsei University (Doctoral dissertation: The expression and function of PD-1 expressing regulatory T cells of cancer patients)

• Professional Experience:

2005-2006: Rotating internship, Severance Hospital, Seoul, Korea
2006-2010: Resident in Internal Medicine, Severance Hospital, Seoul, Korea
2010-2012: Clinical Fellowship, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine.
2012-2015: Clinical assistant professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine.
2016- 2019: Assistant professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine.
2020- current: Associate professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine.

2014- 2018: Vice chief of Lung cancer center in Yonsei Cancer Center
2016- current: Member of PRC (Protocol Review Committee) of KCSG
2017- 2018: Administrator of lung cancer division of KCSG (Korean Cancer Study Group)
2017- current: Member of IRB in Severance Hospital.
2018- 2019: Chief of cancer informatics center in Yonsei Cancer Center
2019 Mar - 2020 Jan: Visiting professor Emory University (in Prof. Rafi Ahmed LAB)

• Professional Organizations:

2012- American Society for Clinical Oncology 2010- Korean Cancer Study Group (KCSG) 2010- Korean Association for Clinical Oncology
2013- Korean Association for the Study of Lung Cancer 2013- The Korean Society for Head & Neck Oncology
2013- Active member of Lung Cancer and Head & Neck Cancer Committee of KCSG

• **Main Scientific Publications:**

1. Bo Ryeong Lee, Sehyun Chae, Jihyun Moon, Myeong Joon Kim, Hankyu Lee, Hyuk Wan Ko, Byoung Chul Cho, Hyo Sup Shim, Daehee Hwang, Hye Ryun Kim, and Sang-Jun Ha Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade JCI Insight. 2020;5(14):e128633. (Correspondence)
2. Charles M. Rudin, Mark M. Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csöszi, Parneet K. Cheema, Delvys Rodriguez-Abreu, Mirjana Wollner, James Chih-Hsin Yang, Julien Mazieres, Francisco J. Orlandi, Alexander Luft, Mahmut Gümüş, Terufumi Kato, Gregory P. Kalemkerian, Yiwen Luo, Victoria Ebiana, M. Catherine Pietanza, and Hye Ryun Kim Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study(senior author) JCO.20.00793 Journal of Clinical Oncology
3. Kim CG, Kim KH, Pyo KH, Xin CF, Hong MH, Ahn BC, Kim Y, Choi SJ, Yoon HI, Lee JG, Lee CY, Park SY, Park SH, Cho BC, Shim HS, Shin EC, Kim HR. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol. 2019 Jul 1;30(7):1104-1113 (Correspondence)
4. Kim HR, Park HJ, Son J, Lee JG, Chung KY, Cho NH, Shim HS, Park S, Kim G, In Yoon H, Kim HG, Jung YW, Cho BC, Park SY, Rha SY, Ha SJ. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. J Immunother Cancer. 2019 Dec 4;7(1):339.
5. Hong MH, Shin SJ, Shin SK, Kim DJ, Zo JI, Shim YM, Lee SE, Cho BC, Park SY, Choi YL, Kim HR High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma. Sci Rep. 2019 Dec 27;9(1):20197 (Correspondence)
6. Kim SY, Lee JY, Kim DH, Joo H-, Yun MR, Jung D, Yun J, Heo SG, Ahn B-, Park CW, Pyo KH, Chun YJ, Hong MH, Kim HR, Cho BC. Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma. Sci Rep. 2019 Dec 27;9(1):19909. (Co-correspondence)
7. Na KJ, Hyun K, Kang CH, Park S, Lee HJ, Park IK, Kim YT, Lee GD, Kim HR, Choi SH, Kim YH, Kim DK, Park SI, Shin S, Cho JH, Kim HK, Choi YS, Kim J, Zo JI, Shim YM, Lee CY, Lee JG, Kim DJ, Paik HC, Chung KY. Predictors of post-thymectomy long-term neurological remission in thymomatous myasthenia gravis: an analysis from a multi-institutional database. Eur J Cardiothorac Surg. 2019 Dec 20